Therapeutic effect of Sirtuin 3 on ameliorating nonalcoholic fatty liver disease: The role of the ERK-CREB pathway and Bnip3-mediated mitophagy

Cited by papers we hold 12

• Mitochondrial quality control in human health and disease · 2024
  No notice
• Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction · 2024
  No notice
• The mitophagy pathway and its implications in human diseases · 2023
  No notice
• Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy · 2023
  No notice
• NAFLD: Mechanisms, Treatments, and Biomarkers · 2022
  No notice
• The sirtuin family in health and disease · 2022
  No notice
• SirT3 activates AMPK-related mitochondrial biogenesis and ameliorates sepsis-induced myocardial injury · 2020
  No notice
• Bax inhibitor 1 preserves mitochondrial homeostasis in acute kidney injury through promoting mitochondrial retention of PHB2 · 2020
  No notice
• Role and Mechanisms of Mitophagy in Liver Diseases · 2020
  No notice
• Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target · 2020
  No notice
• DNA-PKcs promotes alcohol-related liver disease by activating Drp1-related mitochondrial fission and repressing FUNDC1-required mitophagy · 2019
  No notice
• Activation of BNIP3-mediated mitophagy protects against renal ischemia–reperfusion injury · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.